
Author: Vitthia Rama Murti, RPh 15632
Reviewed by: Dr Yong Yi Yi
Review date: 3 November 2026
Evidence grade: B
Commercial interest: Bionutricia has a commercial interest in this subject. Bionutricia Extract supplies a saffron stigma extract powder; see the disclosure below.
Abstract
Background: Crocus sativus (saffron) stigma preparations have been tested in human trials for depression, anxiety, mood, sleep and cognition.
Objective: To report, outcome by outcome, what human trials of saffron stigma preparations found for depression, anxiety, mood, sleep and cognition.
Methods: PubMed was searched on 3 November 2026 with the terms “saffron extract” and “Crocus sativus saffron stigma extract depression anxiety mood sleep cognition”. Ten records were included: six systematic reviews or meta-analyses and four randomised controlled trials.
Results: Saffron supplementation significantly reduced BDI and BAI scores, with no significant effects on HDRS, HARS or POMS (41693488).
Saffron was more effective than placebo in improving cognition, depression, anxiety and sleep disorders (38424688).
Saffron showed a nonsignificant difference from SSRIs in reducing depressive and anxiety symptoms, with fewer adverse events than the SSRI group (38913392).
At 28 mg/day, affron significantly decreased negative mood, with a significant difference from placebo on POMS Total Mood Disturbance (p<0.001); no treatment effect at 22 mg/day (28735826).
Saffron was associated with greater improvement than placebo in the DASS-21 depression score; no evidence of between-group differences in other secondary outcomes; large placebo responses were evident (40414301).
Saffron improved PSQI sleep quality, sleep latency, sleep duration and global scores, whereas placebo did not modify those parameters (33925432).
Saffron was associated with greater improvements than placebo in sleep quality ratings (primary outcome); no significant differences in other questionnaire and sleep diary outcomes (34438361).
Conclusion: Saffron supplementation significantly reduced BDI and BAI scores; HDRS, HARS and POMS were not significant (41693488).
Saffron was more effective than placebo for cognition in the only included record that reports cognition (38424688).
Review methodology
Database: PubMed, searched on 3 November 2026 with the human clinical evidence filter switched on.
Search terms, word for word: “saffron extract”; “Crocus sativus saffron stigma extract depression anxiety mood sleep cognition”.
Included: records that report human trial outcomes, or synthesise human trials, on at least one of the five named outcomes: depression, anxiety, mood, sleep and cognition. Ten records met this standard. Reviews and meta-analyses were included when they report saffron trial results for one of these outcomes.
Excluded:
- PMID 37864351 (2024), a systematic review. Its abstract describes a study that “aims to evaluate the efficacy and safety of saffron extracts in ADHD”. Its outcome is ADHD, which is not one of the five named outcomes.
- PMID 36235697 (2022), a clinical trial. Its abstract describes “a non-randomized clinical trial with two groups, methylphenidate (n = 27) and saffron (n = 36)” in children and adolescents with ADHD, with “hyperactivity symptoms” and “inattention symptoms” as outcomes. ADHD symptoms are not one of the five named outcomes, and the design is not randomised.
- PMID 29464801 (2018), a systematic review. Its abstract reports that “One hundred articles involving 38 botanicals met our criteria” and names saffron, with lavender and passionflower, as producing “benefits comparable to standard anxiolytics and antidepressants”. The review covers 38 botanicals and groups saffron with lavender and passionflower in one statement, so the record carries no saffron-only figure, dose or population.
How records were assessed: each record was read against the five named outcomes. Its design, population and preparation were noted, and it was included or excluded on those grounds. Records were assessed from their published abstracts.
Summary of study findings
PMID 41693488: systematic review and meta-analysis, 2026 (Mahmoudi et al.)
Design: systematic review and meta-analysis of randomised, placebo-controlled trials, with the certainty of evidence assessed by GRADE.
Participants: 1,769 across 34 randomised controlled trials; adults.
Dose and form: saffron supplementation.
Duration: eligible interventions lasted at least four weeks.
Outcome, in the abstract’s words: “Saffron supplementation significantly reduced scores on BDI (14 trials; 817 participants; WMD = -4.39, 95% CI: -6.64 to -2.15, p < 0.001, I2 = 92.3%) and the BAI (6 trials; 339 participants; WMD = -5.06, 95% CI: -8.44 to -1.68, p = 0.003, I2 = 94.8%). No significant effects were observed for the HDRS, HARS, or POMS. The certainty of evidence was rated as moderate according to the GRADE Working Group criteria.”
PMID 38424688: systematic review and meta-analysis, 2024 (Han et al.)
Design: systematic review and meta-analysis of randomised controlled trials, searched up to June 2023. The review assessed cognition, depression, anxiety, sleep disorders, ADHD and OCD; the outcomes reported here are the first four.
Participants: 46 randomised controlled trials; participants “either healthy or suffering from some diseases, including neurological and psychiatric disorders”.
Dose and form: “saffron or its extracts, both alone or in combination with conventional drugs”.
Duration: 4 to 48 weeks.
Outcome, in the abstract’s words: “Saffron was more effective than placebo in improving cognition, depression with an overall effect size of -4.26 (95% CI: -5.76, -2.77), anxiety of -3.75 (95% CI: -5.83, -1.67), and sleep disorders of -1.91 (95% CI: -2.88, -0.93).”
PMID 38913392: meta-analysis, 2025, saffron versus SSRIs (Shafiee et al.)
Design: random-effects meta-analysis of randomised controlled trials comparing a saffron intervention with selective serotonin reuptake inhibitors (SSRIs).
Population: adults with depression or anxiety.
Comparator: SSRIs.
Outcome, in the abstract’s words: “Meta-analysis of 8 studies assessing depression outcomes revealed a nonsignificant difference between saffron and SSRIs in reducing depressive symptoms (SMD = 0.10l 95% CI: -0.09 to 0.29). Four studies reporting anxiety outcomes showed a nonsignificant difference between saffron and SSRIs in reducing anxiety symptoms (SMD = 0.04; 95% CI: -0.22 to 0.29). With regard to safety, participants receiving saffron had fewer adverse events than the SSRI group (risk difference: -0.06; 95% CI: -0.09, -0.04; I2: 0%).”
PMID 30036891: meta-analysis, 2019, mild to moderate depression (Tóth et al.)
Design: meta-analysis reported to PRISMA guidelines. Eleven randomised trials were included in the qualitative analysis and nine were pooled.
Population: patients with mild to moderate depression.
Dose and form: “pharmacological doses of saffron per os”.
Comparators: placebo, and “tested antidepressant drugs” in the abstract’s wording.
Outcome, in the abstract’s words: “saffron has a significant effect on the severity of depression.” and “Available data from randomized, controlled clinical trials support that saffron is significantly more effective than placebo (g = 0.891; 95% CI: 0.369 – 1.412, p = 0.001), and non-inferior to tested antidepressant drugs (g = – 0.246; 95% CI: – 0.495 – 0.004, p = 0.053).”
PMID 28735826: randomised controlled trial, 2017, affron (Kell et al.)
Design: double-blind, parallel, randomised, placebo-controlled trial over 4 weeks.
Participants: 128 participants “self-reporting low mood but not diagnosed with depression”.
Dose and form: affron, “a standardised stigmas extract”, at 28 mg/day or 22 mg/day, or placebo.
Outcomes: the primary outcome was the POMS; the PANAS, DASS-21 and PSQI were also used.
Outcome, in the abstract’s words: “Analysis indicated a significant decrease in negative mood and symptoms related to stress and anxiety at a 28mg/day dose (with a significant difference between 28mg/day and placebo on the POMS Total Mood Disturbance scale, p<0.001, d=-1.10), but no treatment effect at the 22mg/day dose.”
PMID 40414301: randomised controlled trial, 2025, affron (Lopresti et al.)
Design: two-arm, 12-week, parallel-group, randomised, double-blind, placebo-controlled trial.
Participants: 202 adults aged 18 to 70 with depressive symptoms; the objectives describe them as adults “experiencing subclinical depressive symptoms”.
Dose and form: 28 mg of a saffron extract (Affron) daily, or placebo.
Duration: 12 weeks.
Outcome, in the abstract’s words: “On the primary outcome measure, compared to the placebo, saffron was associated with greater improvements in the Depression, Anxiety, and Stress scale – 21 depression score (β: -2.92 points; 95% confidence interval: -5.13, -0.71 points; Cohen’s d = 0.39), with 72.3% of participants in the saffron group achieving a clinically significant change (a reduction of ≥ 7 points) compared to 54.3% of participants in the placebo group (P = 0.010). However, in the other secondary outcomes, there was no evidence of between-group differences. In exploratory analyses across various strata and assumptions, improvements in sleep disturbances (β: -2.72 points; 95% confidence interval: -4.99, -0.46 points; Cohen’s d = 0.44) were identified in a subset of participants with a greater severity of sleep disturbance. There were no serious adverse reactions reported.”
PMID 33925432: randomised controlled trial, 2021, sleep (Pachikian et al.)
Design: randomised, double-blind, controlled clinical trial over 6 weeks.
Participants: 66 subjects randomised, with a “mild to moderate sleep disorder associated with anxiety”.
Dose and form: “a saffron extract (15.5 mg per day)” or placebo (maltodextrin).
Outcome, in the abstract’s words: “Six weeks of saffron supplementation led to an increased time in bed assessed by actigraphy, to an improved ease of getting to sleep evaluated by the LSEQ questionnaire and to an improved sleep quality, sleep latency, sleep duration, and global scores evaluated by the PSQI questionnaire, whereas those parameters were not modified by the placebo.”
PMID 34438361: randomised controlled trial, 2021, sleep (Lopresti et al.)
Design: 28-day, three-arm, parallel-group, double-blind, randomised, placebo-controlled trial.
Participants: 120 adults with “unsatisfactory sleep”.
Dose and form: placebo, 14 mg or 28 mg of “a standardised saffron extract (affron®)”, taken 1 hour before bed.
Primary outcome: sleep quality ratings on the Pittsburgh Sleep Diary.
Outcome, in the abstract’s words: “Compared to the placebo, saffron supplementation was associated with greater improvements in sleep quality ratings (primary outcome measure), mood ratings after awakening, the ISQ total score, and ISQ-insomnia classifications. However, there were no significant differences between the saffron and placebo groups in other questionnaire and sleep diary outcome measures. Sleep improvements were similar for the two administered saffron doses.”
PMID 25384672: systematic review, 2014, depression (Lopresti and Drummond)
Design: systematic review of clinical studies, in which the trials were “randomised, double-blind studies, with placebo or antidepressant controls”.
Participants: depression.
Outcome, in the abstract’s words: “In the systematic review, six studies were identified. In the placebo-comparison trials, saffron had large treatment effects and, when compared with antidepressant medications, had similar antidepressant efficacy.”
PMID 29575228: systematic review, 2018, psychiatric disorders (Sarris)
Design: ten-year update of a systematic review of herbal medicines in psychiatric disorders, covering “clinical trial evidence for 24 herbal medicines in 11 psychiatric disorders”. Saffron is one of the 24 herbs. The grading below is the review’s judgement across all of them, and its saffron statement concerns major depressive disorder only.
Outcome, in the abstract’s words: “High-quality evidence was found to exist for the use of […] Hypericum perforatum (St John’s wort) and Crocus sativus (saffron) for major depressive disorder.”
Evidence-quality assessment
Grade B. Grade A requires consistent findings from more than one human randomised trial or a meta-analysis of such trials. The body of evidence is not consistent across all outcomes, so the evidence is graded B. The reasons:
- Consistency:
BDI and BAI scores significantly reduced, with no significant effects on HDRS, HARS or POMS; heterogeneity was high (I2 92.3% for BDI and 94.8% for BAI) (41693488).
Saffron was more effective than placebo for depression and anxiety (38424688).
Nonsignificant difference from SSRIs in depression and anxiety scores (38913392).
Significantly more effective than placebo for depression severity (30036891).
Greater improvement than placebo in DASS-21 depression score (40414301). - Study design: four randomised controlled trials (28735826, 40414301, 33925432, 34438361) and six reviews or meta-analyses.
- Size:
66 subjects randomised (33925432).
128 participants (28735826).
120 adults with unsatisfactory sleep (34438361).
202 adults with depressive symptoms (40414301).
34 randomised trials and 1,769 participants (41693488). - Directness:
affron, a standardised stigmas extract, at 28 mg/day and 22 mg/day (28735826).
affron, a standardised saffron extract, at 14 mg and 28 mg (34438361).
A saffron extract at 15.5 mg per day (33925432).
Saffron supplementation across 34 randomised trials (41693488).
Saffron or its extracts, alone or with conventional drugs (38424688).
Pharmacological doses of saffron per os (30036891). - Transfer:
Adults self-reporting low mood but not diagnosed with depression (28735826).
Adults aged 18 to 70 with subclinical depressive symptoms (40414301).
Adults with unsatisfactory sleep (34438361).
Subjects with mild to moderate sleep disorder associated with anxiety (33925432).
Patients with mild to moderate depression (30036891).
Participants healthy or suffering from diseases including neurological and psychiatric disorders (38424688). - Downgrades:
Heterogeneity above 90% for BDI and BAI, and HDRS, HARS and POMS not significant (41693488).
Four-week trial (28735826).
Six-week trial (33925432).
28-day trial (34438361).
12-week trial (40414301).
Cognition covered by one broad review only (38424688).
Limitations
Records were assessed from their published abstracts rather than from full texts.
- No included trial reports a crocin content or tests a crocin-standardised product.
- The 2026 meta-analysis reports high heterogeneity (I2 92.3% for BDI and 94.8% for BAI) (41693488).
- HDRS, HARS and POMS were not significant in the 2026 meta-analysis (41693488).
- The 2025 trial found no between-group difference on its other secondary outcomes (40414301).
- The 2021 trial found no significant difference on its other questionnaire and sleep diary outcomes (34438361).
- Four-week trial (28735826).
- Six-week trial (33925432).
- 28-day trial (34438361).
- 12-week trial (40414301).
- Cognition rests on one broad systematic review. The abstract of 38424688 reports that saffron was more effective than placebo in improving cognition.
- The trials used different preparations: 28735826 affron at 28 and 22 mg/day; 34438361 affron at 14 and 28 mg; 40414301 saffron extract Affron at 28 mg; 33925432 saffron extract at 15.5 mg/day; 38424688 saffron or its extracts.
- 33925432 used actigraphy alongside the LSEQ and PSQI questionnaires (33925432).
- 34438361 measured evening salivary melatonin and cortisol alongside its sleep questionnaires (34438361).
- The 2017 trial’s abstract names “the self-reporting nature of both the screening and the testing” as its main weakness (28735826).
- The 2025 trial reports “Large placebo responses” (40414301).
- The 2019 meta-analysis reports its non-inferiority result as “non-inferior to tested antidepressant drugs (g = – 0.246; 95% CI: – 0.495 – 0.004, p = 0.053)” (30036891).
- The 2018 review’s grading covers 24 herbal medicines in 11 psychiatric disorders, and its saffron statement concerns major depressive disorder only (29575228).
Conclusion
On the question of what human trial evidence reports by outcome for depression, anxiety, mood, sleep and cognition:
Saffron supplementation significantly reduced BDI and BAI scores; HDRS, HARS and POMS were not significant (41693488).
Saffron was more effective than placebo for cognition (38424688).
Nonsignificant difference from SSRIs in depressive and anxiety symptoms, with fewer adverse events (38913392).
Greater improvement than placebo in negative mood at 28 mg/day (28735826).
Greater improvement than placebo in the DASS-21 depression score (40414301).
Saffron improved PSQI sleep quality, sleep latency, sleep duration and global scores; placebo did not modify those parameters (33925432).
Greater improvement than placebo in sleep quality ratings (34438361).
References
- Mahmoudi R, Mohammadi-Sartang M, Servatyari K, Rafieipour N. Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials. Nutritional neuroscience. 2026;29(7):816-837. PMID: 41693488. doi:10.1080/1028415X.2025.2602153
- Han S, Cao Y, Wu X, Xu J, Nie Z, Qiu Y. New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms. Phytotherapy research : PTR. 2024;38(5):2276-2302. PMID: 38424688. doi:10.1002/ptr.8110
- Shafiee A, Jafarabady K, Seighali N, Mohammadi I, Rajai Firouz Abadi S, Abhari FS, et al. Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials. Nutrition reviews. 2025;83(3):e751-e761. PMID: 38913392. doi:10.1093/nutrit/nuae076
- Tóth B, Hegyi P, Lantos T, Szakács Z, Kerémi B, Varga G, et al. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. Planta medica. 2019;85(1):24-31. PMID: 30036891. doi:10.1055/a-0660-9565
- Kell G, Rao A, Beccaria G, Clayton P, Inarejos-García AM, Prodanov M. affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complementary therapies in medicine. 2017;33:58-64. PMID: 28735826. doi:10.1016/j.ctim.2017.06.001
- Lopresti AL, Smith SJ, Marx W, Díez-Municio M, Morán-Valero MI. An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of nutrition. 2025;155(7):2300-2311. PMID: 40414301. doi:10.1016/j.tjnut.2025.05.024
- Pachikian BD, Copine S, Suchareau M, Deldicque L. Effects of Saffron Extract on Sleep Quality: A Randomized Double-Blind Controlled Clinical Trial. Nutrients. 2021;13(5). PMID: 33925432. doi:10.3390/nu13051473
- Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep medicine. 2021;86:7-18. PMID: 34438361. doi:10.1016/j.sleep.2021.08.001
- Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human psychopharmacology. 2014;29(6):517-27. PMID: 25384672. doi:10.1002/hup.2434
- Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytotherapy research : PTR. 2018;32(7):1147-1162. PMID: 29575228. doi:10.1002/ptr.6055
Disclosure of commercial interest
Bionutricia has a commercial interest in this subject. Saffron appears in the Bionutricia Extract product line as “Saffron Yellow (Crocus sativus) Standardized Extract Powder”. Its product page states its actives as “Pure 100:1 Saffron Yellow Crocus Sativus Extract” and names crocin as the primary standardisation marker. Bionutricia Extract supplies this as an ingredient. bionutricia.com manufactures finished formats, and this review makes no claim about any finished format.
The literature calls this material “saffron”, “saffron stigma extract” or “Crocus sativus stigma extract”. The product line calls it “Saffron Yellow Crocus Sativus Extract”. These names describe the same thing, an extract of saffron stigmas. The trials that tested “affron” studied a named extract that is not this product, and their results are reported as results for affron.
This review was not commissioned or paid for by a third party. Its findings and evidence grade were not altered to favour any product. Nothing here is medical advice, and nothing in this review claims that a product treats, prevents or cures any condition.
Author biography
Vitthia Rama Murti, Registered Pharmacist (RPh 15632). Subject scope: formulation, excipients, stability, tolerability and safety; clinical evidence, including human trials, indications, dosing and clinical outcomes.
Dr Yong Yi Yi (reviewer) holds a PhD in Science from Monash University, in food science and technology, microbiology and chemistry, and a BSc (Hons) in Medical Bioscience from Monash University.
Review history
Date written: 3 November 2026.
Reviewed by: Dr Yong Yi Yi (reviewed and signed off this review on 3 November 2026).
Date reviewed: 3 November 2026.
